MediWound Ltd.
NASDAQ:MDWDBiotechnology
-$0.09 today
- Market cap
- $176.61M
- Beta
- 0.15
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$2.03
Volume 0.16M
Average 0.09M
MDWD EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
MediWound Ltd.NASDAQ: MDWD
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$2.59M, compared with -$363K a year earlier. Trailing-twelve-month EBITDA was -$14.84M.
Context
- EBITDA amounted to 126.6% of revenue in FY2025, down 11.5 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$19.87M (+7.5%) for the fiscal year ending Dec 2026, a slowdown from the +23.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$2.59M+49.9% QoQ
- Last fiscal yearDec 2025
- -$21.47M+23.1% YoY
- LTMMar 2026
- -$14.84M+39.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -613.8% | -71.6% | +542.2 pp |
| 1 year | +23.1% | +7.5% | -15.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (21.47M) USD
- Year-over-year change
- +23.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (21.47M) | +23.1% |
| FY2024 | 2024-12-31 | (27.93M) | -481.7% |
| FY2023 | 2023-12-31 | (4.8M) | +73.7% |
| FY2022 | 2022-12-31 | (18.25M) | -60.3% |
| FY2021 | 2021-12-31 | (11.38M) | — |
EBITDA vs competitors
How MDWD compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +39.0% is the 2nd highest of 9, against a peer median of -57.7%.
- EBITDA amounts to 102.5% of revenue for MDWD, versus a peer median of 1509.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$14.84M USD | +39.0% | — | 102.5% | |
| LTM Mar 2026 | -$35.22M USD | — | — | — | |
| LTM Sep 2026 | -$35.76M USD | -89.6% | — | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | -$45.49M USD | -75.7% | — | — |
| LTM Mar 2026 | -$52.72M USD | +20.1% | — | 161.1% | |
| LTM Mar 2026 | -$62.94M USD | -39.6% | — | — | |
| LTM Mar 2026 | -$69.83M USD | -147.0% | — | — | |
| LTM Mar 2026 | -$75.72M USD | +45.7% | — | 135.5% | |
| FY2025 | -€128.15M EUR | +23.0% | — | 2858.6% | |
| LTM Mar 2026 | -$158.55M USD | -341.7% | — | 8932.3% | |
| Peer median (excluding MDWD) | — | -57.7% | — | 1509.8% | |
Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 23.76M | 26.5M | 18.69M | 20.22M | 16.96M |
| Cost of Revenue | 14.99M | 13.33M | 15.11M | 17.59M | 13.71M |
| Gross Profit | 8.77M | 13.17M | 3.58M | 2.63M | 3.25M |
| Gross Margin | 36.9% | 49.7% | 19.1% | 13.0% | 19.2% |
| Research & Development | 10.26M | 10.18M | 7.47M | 8.88M | 14.32M |
| Selling, General & Admin | 9.45M | 10.37M | 11.38M | 12.91M | 13.93M |
| Operating Expenses | 19.99M | 20.83M | 19.08M | 22.02M | 28.53M |
| Depreciation & Amortization | 1.24M | 1.27M | 1.3M | 1.48M | 1.86M |
| EBITDA | (11.38M) | (18.25M) | (4.8M) | (27.93M) | (21.47M) |
| EBITDA Margin | -47.9% | -68.9% | -25.7% | -138.1% | -126.6% |
| Operating Income | (11.22M) | (7.66M) | (15.5M) | (19.38M) | (25.28M) |
| Operating Margin | -47.2% | -28.9% | -83.0% | -95.8% | -149.1% |
| Interest Income | 11K | 270K | 2.34M | 2.05M | 1.86M |
| Interest Expense | 167K | 162K | 335K | 561K | 663K |
| Other Income / Expenses | (2.3M) | (11.86M) | 8.97M | (10.78M) | 1.57M |
| Income Before Tax | (13.52M) | (19.52M) | (6.53M) | (30.16M) | (23.71M) |
| Pre-Tax Margin | -56.9% | -73.7% | -35.0% | -149.2% | -139.8% |
| Income Tax Expense | 27K | 78K | 185K | 61K | 169K |
| Net Income | (13.55M) | (19.6M) | (6.72M) | (30.22M) | (23.88M) |
| Net Margin | -57.0% | -74.0% | -35.9% | -149.5% | -140.8% |
| EPS (Basic) | (3.48) | (3.93) | (0.75) | (3.03) | (2.10) |
| EPS (Diluted) | (3.48) | (3.93) | (0.75) | (3.03) | (2.10) |
| Weighted Avg Shares | 3.89M | 4.99M | 9.01M | 9.96M | 11.38M |
| Weighted Avg Shares (Diluted) | 3.89M | 4.99M | 9.01M | 9.96M | 11.38M |
MediWound Ltd.
NASDAQ:MDWD
Intrinsic Alpha fair value
Locked
Current Price
$13.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.